Fractalkine in rheumatoid arthritis and allied conditions

References

• Luscinskas FW, Gimbrone MA. Endothelial-dependent mecha-nisms in chronic inflammatory leukocyte recruitment. Annu Rev Med 1996;47:413–21.
   PubMedGoogle Scholar
• Cines DB, Pollak ES, Buck CA, LOSC2170 J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the patho-physiology of vascular disorders. Blood 1998;91:3527–61.
   Google Scholar
• Montovani A, Buss°lino F, Introna M. Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today 1997;18:231–40.
   PubMedGoogle Scholar
• Taub DD, Oppenheim JJ. Chemokines, inflammation and the im-mune system. Ther Immunol 1994;1:229–46.
   PubMedGoogle Scholar
• Rollins BJ. Chemokines. Blood 1997;90:909–28.
   PubMed Web of Science ®Google Scholar
• Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemokines-CXC and CC chemokines. Adv Immunol 1994;55: 97–179.
   Google Scholar
• Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 1994;12:593–633.
   PubMed Web of Science ®Google Scholar
• Gerard C, Rollins BJ. Chemokine and disease. Nat Immunol 2001;2:108–15.
   PubMed Web of Science ®Google Scholar
• Proudfoot AEI. Chemokine receptors: Multifaceted therapeutic targets. Nat Rev Immunol 2002;2:106–15.
   PubMed Web of Science ®Google Scholar
• Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Ross D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997;385:640–4.
   PubMed Web of Science ®Google Scholar
• Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, et al. Identification and molecular characterization of Fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521–30.
   PubMed Web of Science ®Google Scholar
• Goda S, Imai T, Yoshie 0, Yoneda 0, Inoue H, Nagano Y, et al. 32. CX3C-chemokine, fractalkine enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and independent 33. mechanisms. J Immunol 2000;164: 4313–20.
   Google Scholar
• Umehara H, Bloom ET, Okazaki T, Domae N, Imai T. Fractalkine 34. and vascular injury. Trends Immunol 2001;22: 602–7.
   Google Scholar
• Umehara H, Bloom ET, Okazaki T, Yoshie 0, Imai T. Fractalkine 35. and vascular biology: from basic research to clinical diseases (Review). Arterioscler Thromb Vasc Biol 2004;24: 34–40.36.
   Google Scholar
• Pan Y, Lioyd C, Zhou H, Dolich S, Deeds J, Gonzalo J-A, et al. Neurotactin, a membrane-anchored chemokine upregulated in 37. brain inflammation. Nature 1997;387: 611–7.
   Google Scholar
• Fong AM, Erickson HP, Zachariah JP, Poon S, Schamberg NJ, Imai T, et al. Ultrastructure and function of the fractalkine mucin domain in CX3C chemokine domain presentation. J Biol Chem 38. 2000;275:3781–6.
   PubMedGoogle Scholar
• Haskell CA, Cleary MD, Charo IF. Unique role of the chemokine domain of fractalkine in cell capture. J Biol Chem 2000;275:34183-39. 9.
   Google Scholar
• Umehara H, Goda S, Imai T, Nagano Y, Minami Y, Tanaka Y, et al. Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunol Cell 40. Biol 2001;79: 298–302.
   Google Scholar
• Kourilsky P, Truffa-Bachi P. Cytokine fields and the polarization of the immune response. Trends Immunol 2001;22:502–9.
   PubMedGoogle Scholar
• Rhodes SG, Graham SP. Is 'timing' important for cytokine polar- 41. ization? Trends Immunol 2002;23:246–9.
   PubMed Web of Science ®Google Scholar
• Yoshie 0, Imai T, Nomiyama H. Related article chemokines in immunity. Adv Immunol 2001;78:57-110.42.
   Google Scholar
• Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000;18:593-620.43.
   Google Scholar
• Shresta S, Pham CT, Thomas DA, Grauber TA, Ley TJ. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 1998;10:581-7.44.
   Google Scholar
• Hamann D, Roos MTL, van Lier RAW. Face and phases of human CD8' T-cell development. Immunol Today 1999;20:177–80.
   Google Scholar
• Tomiyama H, Matsuda T, Takiguchi M. Differentiation of human 45. CD8+ T cells from a memory to memory/effector phenotype. J Immunol 2002;168: 5538–50.
   Google Scholar
• Nishimura M, Umehara H, Nakayama T, Yoneda 0, Hieshima K, Kakizaki M, et al. Dual functions of fractalkine/CX3CR1 in 46. trafficking of circulating cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002;168: 6173–80.
   Google Scholar
• Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine 47. MIP-113. Nature 1993;361: 79–82.
   Google Scholar
• Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie 0, Imai T, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic 48. flow. J Exp Med 1998;188: 1413–9.
   Google Scholar
• Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid 49. flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem 1999;274: 10053–8.
   Google Scholar
• Moretta L, Ciccone E, Mingari MC, Biassoni R, Moretta A. Human natural killer cells: Origin, donality, specificity, and recep- 50. tors. Adv Immunol 1993;55: 341–80.
   Google Scholar
• Umehara H, Huang J-Y, Kono T, Tabassam FH, Okazaki T, Bloom ET, et al. Involvement of protein tyrosine kinase p72Yk and phosphatidylinositol 3-kinase in CD2-mediated granular exocyto- 51. sis in natural killer cell line. J Immunol 1997;159:1200-7. Lanier LL. On guard-activating NK cell receptors. Nat Immunol 2001;2:23-7. Yoneda 0, Imai T, Gouda S, Inoue H, Yamauchi A, Okazaki T, et al. NK cell-mediated vascular injury. J Immunol 2000;164:4055-62. Seaman WE. Natural killer cells and natural killer T cells. Arthritis Rheum 2000;43:1204-17. Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Thl/Th2 polarization. Immunol Today 2000;21:479-83. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002;2:933-44. Yoneda 0, Imai T, Inoue H, Nishimura M, Minami Y, Bloom ET, et al. Membrane bound form of fractalkine induces IFN-y produc-tion by NK cells: a role for Thl response. Eur J Immunol 2003;33: 53–8. Ruth JH, Rottman JB, Katschke KJ Jr, Qin S, Wu L, LaRosa G, et al. Selective lymphocytes chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 2001;44:2750-60. Ruth JH, Volin MV, Haines III GK, Woodruff DC, Katschke Jr KJ, Woods JM, et al. Fractalkine, a novel chemokine in rheuma-toid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum. 2001;44:1568-81. Nanki T, Imai T, Nagasaka K, Urasaki Y, Nonomura Y, Taniguchi K, et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002;46:2878-83. Sawai H, Park YW, Roberson J, Imai T, Goronzy JJ, Weyand CM. T cell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis. Arthritis Rheum 2005;52:1392-401. Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE. Fractalkine: a novel angiogenic chemokine in rheuma-toid arthritis. Am J Pathol 2001;159:1521-30. Nanki T, Urasaki Y, Imai T, Nishimura M, Muramoto K, Kubota T, et al. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J Immunol 2004;173:7010-6. Yajima N, Kasama T, Isozaki T, Odai T, Matsunawa M, Negishi M, et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus. Arthritis Rheum 2005;52:1670-5. Chen S, Bacon KB, Li L, Garcia GE, Xia Y, Lo D, et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med 1998;188:193-8. Feng L, Chen S, Garcia GE, Xia Y, Siani MA, Botti P, et al. Prevention of crescent glomerulonephritis by immunoneutrali-zation of the fractalkine receptor CX3CR1. Kidney Int 1999;56: 612–20. Inoue A, Hasegawa H, Kohno M, Ito MR, Terada M, Imai T, et al. Antagonist of fractalkine (CX3CL1) delays the inhibition and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 2005;52:1522-33. Hasegawa M, Sato S, Echigo T, Ysui M, Takehara K. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis 2005;64:21-8. Suzuki F, Nanki T, Imai T, Kikuchi H, Hirohata S, Kohsaka H, et al. Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL/J mice. J Immunol 2005;175:6987-96. Balabanian K, Foussat A, Dormuller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, et al. CX3C chemokine fractalkine in pulmo-nary arterial hypertension. Am J Respir Crit Care Med 2002;165: 1419–25. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22: 358–63.
   Google Scholar
• Lanier LL. On guard-activating NK cell receptors. Nat Immunol 2001;2:23–7.
   PubMed Web of Science ®Google Scholar
• Yoneda O, Imai T, Gouda S, Inoue H, Yamauchi A, Okazaki T, et al. NK cell-mediated vascular injury. J Immunol 2000;164:4055–62.
   PubMed Web of Science ®Google Scholar
• Seaman WE. Natural killer cells and natural killer T cells. Arthritis Rheum 2000;43:1204–17.
   PubMedGoogle Scholar
• Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1/Th2 polarization. Immunol Today 2000;21: 479–83.
   Google Scholar
• Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002;2:933–44.
   PubMed Web of Science ®Google Scholar
• Yoneda O, Imai T, Inoue H, Nishimura M, Minami Y, Bloom ET, et al. Membrane bound form of fractalkine induces IFN-� production by NK cells: a role for Th1 response. Eur J Immunol 2003;33: 53–8.
   PubMedGoogle Scholar
• Ruth JH, Rottman JB, Katschke KJ Jr, Qin S, Wu L, LaRosa G, et al. Selective lymphocytes chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 2001;44:2750–60.
   PubMedGoogle Scholar
• Ruth JH, Volin MV, Haines III GK, Woodruff DC, Katschke Jr KJ, Woods JM, et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum. 2001;44:1568–81.
   PubMed Web of Science ®Google Scholar
• Nanki T, Imai T, Nagasaka K, Urasaki Y, Nonomura Y, Taniguchi K, et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002;46:2878–83.
   PubMed Web of Science ®Google Scholar
• Sawai H, Park YW, Roberson J, Imai T, Goronzy JJ, Weyand CM. T cell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis. Arthritis Rheum 2005;52:1392–401.
   PubMed Web of Science ®Google Scholar
• Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 2001;159:1521–30.
   PubMed Web of Science ®Google Scholar
• Nanki T, Urasaki Y, Imai T, Nishimura M, Muramoto K, Kubota T, et al. Inhibition of fractalkine ameliorates murine collageninduced arthritis. J Immunol 2004;173:7010–6.
   PubMed Web of Science ®Google Scholar
• Yajima N, Kasama T, Isozaki T, Odai T, Matsunawa M, Negishi M, et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus. Arthritis Rheum 2005;52:1670–5.
   PubMed Web of Science ®Google Scholar
• Chen S, Bacon KB, Li L, Garcia GE, Xia Y, Lo D, et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med 1998;188:193–8.
   PubMed Web of Science ®Google Scholar
• Feng L, Chen S, Garcia GE, Xia Y, Siani MA, Botti P, et al. Prevention of crescent glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1. Kidney Int 1999;56: 612–20.
   PubMed Web of Science ®Google Scholar
• Inoue A, Hasegawa H, Kohno M, Ito MR, Terada M, Imai T, et al. Antagonist of fractalkine (CX3CL1) delays the inhibition and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 2005;52:1522–33.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Sato S, Echigo T, Ysui M, Takehara K. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis 2005;64: 21–8.
   Google Scholar
• Suzuki F, Nanki T, Imai T, Kikuchi H, Hirohata S, Kohsaka H, et al. Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL/J mice. J Immunol 2005;175:6987–96.
   PubMed Web of Science ®Google Scholar
• Balabanian K, Foussat A, Dormuller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, et al. CX3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;165: 1419–25.
   Google Scholar
• Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358–63.
   PubMed Web of Science ®Google Scholar